Tidemark’s West Pharmaceutical WST Stock Holding History

Tidemark’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$359	Hold	1	–	–	﹤0.01%	850
2026 Q1	$251	Buy	+1	New	+$249	﹤0.01%	844

Other funds holding WST

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Tidemark's WST Position: Q2 2026 in Review

Tidemark held its West Pharmaceutical (WST) position steady in Q2 2026 at 1 share worth $359. The position accounts for ﹤0.01% of the portfolio, ranked #850.

Tidemark first reported a position in WST in Q1 2026 and has held it in 2 quarters since. 830 funds tracked by Wall St. Rank hold WST as of Q2 2026.

Tidemark held 1 share of West Pharmaceutical worth $359 as of Q2 2026.
Tidemark left its West Pharmaceutical share count unchanged in Q2 2026.
West Pharmaceutical made up ﹤0.01% of Tidemark's portfolio in Q2 2026, its #850 holding.
Tidemark first reported a position in West Pharmaceutical in Q1 2026 and has held it in 2 quarters since.
830 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on Tidemark's 13F filing for Q2 2026, filed 10 Aug 2026.